Table 1 Baseline characteristics of patients with NSCLC who received neoadjuvant therapy
Variables | LODDS<-1.07 | -1.07 ≤ LODDS<-0.27 | LODDS≥-0.27 | P |
|---|---|---|---|---|
n = 866 | n = 895 | n = 298 | ||
Age | 0.359 | |||
≤ 60 years old | 365 (42.1%) | 405 (45.3%) | 142 (47.7%) | |
61-67 years old | 218 (25.2%) | 229 (25.6%) | 70 (23.5%) | |
≥ 68 years old | 283 (32.7%) | 261 (29.2%) | 86 (28.9%) | |
Gender | 0.003 | |||
Female | 381 (44.0%) | 393 (43.9%) | 163 (54.7%) | |
Male | 485 (56.0%) | 502 (56.1%) | 135 (45.3%) | |
Race | 0.029 | |||
White | 729 (84.2%) | 740 (82.7%) | 243 (81.5%) | |
Black | 85 (9.8%) | 84 (9.4%) | 21 (7.0%) | |
Other | 52 (6.0%) | 71 (7.9%) | 34 (11.4%) | |
Marital status | 0.65 | |||
Married | 543 (62.7%) | 588 (65.7%) | 189 (63.4%) | |
Unmarried | 121 (14.0%) | 107 (12.0%) | 37 (12.4%) | |
Separated/Divorced/Widowed | 202 (23.3%) | 200 (22.3%) | 72 (24.2%) | |
Laterality | < 0.001 | |||
Right | 481 (55.5%) | 548 (61.2%) | 207 (69.5%) | |
Left | 385 (44.5%) | 347 (38.8%) | 91 (30.5%) | |
Primary site | < 0.001 | |||
Main bronchus | 24 (2.8%) | 19 (2.1%) | 6 (2.0%) | |
Upper lobe | 642 (74.1%) | 584 (65.3%) | 181 (60.7%) | |
Middle lobe | 22 (2.5%) | 41 (4.6%) | 20 (6.7%) | |
Lower lobe | 162 (18.7%) | 227 (25.4%) | 83 (27.9%) | |
Overlapping lesion of lung | 16 (1.8%) | 24 (2.7%) | 8 (2.7%) | |
Histologic type | < 0.001 | |||
Adenocarcinoma | 343 (39.6%) | 451 (50.4%) | 205 (68.8%) | |
Squamous cell | 365 (42.1%) | 291 (32.5%) | 57 (19.1%) | |
Other | 158 (18.2%) | 153 (17.1%) | 36 (12.1%) | |
Differentiation | 0.032 | |||
Grade I | 32 (3.7%) | 29 (3.2%) | 9 (3.0%) | |
Grade II | 224 (25.9%) | 238 (26.6%) | 101 (33.9%) | |
Grade III | 403 (46.5%) | 417 (46.6%) | 138 (46.3%) | |
Grade IV | 33 (3.8%) | 23 (2.6%) | 2 (0.7%) | |
Unknown | 174 (20.1%) | 188 (21.0%) | 48 (16.1%) | |
T | < 0.001 | |||
T1 | 91 (10.5%) | 147 (16.4%) | 58 (19.5%) | |
T2 | 208 (24.0%) | 257 (28.7%) | 129 (43.3%) | |
T3 | 279 (32.2%) | 270 (30.2%) | 67 (22.5%) | |
T4 | 288 (33.3%) | 221 (24.7%) | 44 (14.8%) | |
N | ||||
N0 | 447 (51.6%) | 178 (19.9%) | 0 (0.0%) | < 0.001 |
N1 | 112 (12.9%) | 198 (22.1%) | 42 (14.1%) | |
N2 | 293 (33.8%) | 502 (56.1%) | 246 (82.6%) | |
N3 | 14 (1.6%) | 17 (1.9%) | 10 (3.4%) | |
Regional nodes examined | 13.0 (9.0-20.0) | 9.0 (4.0-15.0) | 9.0 (5.0-15.0) | < 0.001 |
Regional nodes positive | .0 (0.0-0.0) | 1.0 (0.0-2.0) | 5.0 (2.0-9.0) | < 0.001 |
Surgery | 0.418 | |||
Sublobectomy | 23 (2.7%) | 39 (4.4%) | 11 (3.7%) | |
Lobectomy | 676 (78.1%) | 691 (77.2%) | 233 (78.2%) | |
Pneumonectomy | 167 (19.3%) | 165 (18.4%) | 54 (18.1%) | |
Radiotherapy | 0.082 | |||
No/Unknown | 291 (33.6%) | 275 (30.7%) | 80 (26.8%) | |
Yes | 575 (66.4%) | 620 (69.3%) | 218 (73.2%) | |
Chemotherapy | 0.008 | |||
No/Unknown | 24 (2.8%) | 15 (1.7%) | 0 (0.0%) | |
Yes | 842 (97.2%) | 880 (98.3%) | 298 (100.0%) | |